Biomarin Pharmaceutical Inc (BMRN) Files Form 4 Insider Selling : Daniel K Spiegelman Sells 3,769 Shares

Biomarin Pharmaceutical Inc (BMRN): Daniel K Spiegelman , EVP, Chief Financial Officer of Biomarin Pharmaceutical Inc sold 3,769 shares on May 23, 2016. The Insider selling transaction was reported by the company on May 25, 2016 to the Securities and Exchange Commission. The shares were sold at $87.07 per share for a total value of $328,184.16 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 19, 2016, Robert Baffi (EVP, Technical Operations) sold 5,000 shares at $87.05 per share price.On May 10, 2016, George Eric Davis (EVP, General Counsel) sold 14,658 shares at $85.44 per share price.Also, On May 9, 2016, Jean Jacques Bienaime (Chief Executive Officer) sold 50,000 shares at $80.15 per share price.On May 4, 2016, Jeffrey Robert Ajer (EVP, Chief Commercial Officer) sold 415 shares at $86.03 per share price.

BioMarin Pharmaceutical: On Friday, May 20, 2016 heightened volatility was witnessed in BioMarin Pharmaceutical which led to swings in the share price. The shares opened for trading at $84.94 and hit $86.63 on the upside , eventually ending the session at $86.45, with a gain of 2.01% or 1.7 points. The heightened volatility saw the trading volume jump to 8,69,116 shares. The 52-week high of the share price is $151.75 and the company has a market cap of $14,032,737 M . The 52-week low of the share price is at $62.12.

BioMarin Pharmaceutical Money Flow Index Chart

Company has been under the radar of several Street Analysts.BioMarin Pharmaceutical is Upgraded by Robert W. Baird to Outperform and the brokerage firm has set the Price Target at $110. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Mar 8, 2016.BioMarin Pharmaceutical is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 107 from a previous price target of $105 .The Rating was issued on Mar 3, 2016.BioMarin Pharmaceutical is Reiterated by Wedbush to Neutral while Lowering the Price Target of the company shares to $ 105 from a previous price target of $117 . The Rating was issued on Feb 29, 2016.BioMarin Pharmaceutical is Reiterated by RBC Capital Mkts to Outperform while Lowering the Price Target of the company shares to $ 125 from a previous price target of $155 . The Rating was issued on Feb 26, 2016.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company’s product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).

Leave a Reply

BioMarin Pharmaceutical - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioMarin Pharmaceutical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.